Recent Updates
Recently added Catalysts

BMS-962476

Phase 1

Atherosclerosis | Monoclonal antibody | Cardiovascular |Bristol-Myers Squibb Company|Last Updated: Sep 4, 2013

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindCONTROLLED
Total Trials1
Total Enrollment66
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01587365Single Ascending Dose Safety Study of BMS-962476 in Healthy Subjects and Patients With Elevated Cholesterol on StatinsPHASE1 COMPLETED 66May 1, 2012May 1, 2013Sep 4, 20131 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Safety and tolerability of BMS-962476 as measured by the number of subjects with serious adverse events, deaths or discontinuations due to adverse events (AEs), AEs of injection site reactions, or potentially clinically significant changes in vital signs
Up to Day 43
Secondary Endpoints
Pharmacodynamic effects of single subcutaneous (SC) and intravenous (IV) doses of BMS-962476
Up to Day 43
Maximum observed plasma concentration (Cmax) of single dose pharmacokinetics (PK) and dose proportionality of BMS-962476 following SC and IV administration
17 time points up to Day 43
Time of maximum observed plasma concentration (Tmax) of single dose pharmacokinetics (PK) and dose proportionality of BMS-962476 following SC and IV administration
17 time points up to Day 43
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Panel 1: BMS-962476 SC (0.01 mg/Kg) or PlaceboEXPERIMENTALBMS-962476 0.01 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
Panel 2: BMS-962476 SC (0.03 mg/Kg) or PlaceboEXPERIMENTALBMS-962476 0.03 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
Panel 3: BMS-962476 SC (0.1 mg/Kg) or PlaceboEXPERIMENTALBMS-962476 0.1 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
Panel 4: BMS-962476 SC (0.3 mg/Kg) or PlaceboEXPERIMENTALBMS-962476 0.3 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
Panel 5: BMS-962476 IV (0.3 mg/Kg) or PlaceboEXPERIMENTALBMS-962476 0.3 mg/kg or Placebo matching with BMS-962476 0 mg liquid intravenously (IV), Single Dose, 1 day
Panel 6: BMS-962476 IV (1.0 mg/Kg) or PlaceboEXPERIMENTALBMS-962476 1.0 mg/kg or Placebo matching with BMS-962476 0 mg liquid intravenously (IV), Single Dose, 1 day
Panel 7: Statin + BMS-962476 SC (0.1 mg/Kg) or PlaceboEXPERIMENTALBMS-962476 0.1 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
Panel 8: Statin + BMS-962476 SC (0.3 mg/Kg) or PlaceboEXPERIMENTALBMS-962476 0.3 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
Interventions
NameTypeDescription
BMS-962476BIOLOGICAL -
Placebo matching with BMS-962476BIOLOGICAL -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 65 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Healthy population * Untreated low density lipoprotein cholesterol (LDL-c) ≥ 130 and ≤ 190 mg/dL and triglycerides ≤ 200 mg/dL * Body Mass Index (BMI) of 18 to 35 kg/m2 inclusive * Men and women, ages 18 to 65 years, inclusive * Statin population * Patients with hype...

Countries:United States
Unlock Eligibility Criteria